Boehringer Ingelheim 1st-half 2016 sales boosted by new drugs

In the first half of 2016, Germany’s Boehringer Ingelheim generated total net sales of around 7.3 billion euros ($8.15 billion), which after currency adjustment represents an increase of 2% compared with the same period last year (-1% in euro terms), the company announced this morning.

Excluding the US generics business Roxane, which was sold in February, currency-adjusted growth in the first six months of the financial year amounted to as much as 5% (+1% in euro terms). The family-owned pharma major does not publish earnings figures on a quarterly basis.

Boehringer Ingelheim reported currency-adjusted growth in all its core businesses in the first half of 2016. At the same time, the company achieved key strategic milestones by signing contracts to exchange businesses with Sanofi and completing the internal restructuring of its human pharmaceuticals business. For the current year, Boehringer Ingelheim is still expecting a slight year-on-year increase in currency-adjusted net sales.